Can't make insulin? That might not be a problem, according to Dr. Roger Unger, the lead researcher on a mouse study out of UT Southwestern Medical Center. As Dr. Unger stated in a press release, his findings "suggest that if there is no glucagon, it doesn't matter if you don't have insulin....In adulthood, at least with respect to glucose metabolism, the role of insulin is to control glucagon. And if you don't have glucagon, then you don't need insulin...If diabetes is defined as restoration of glucose homeostasis to normal, then this treatment can perhaps be considered very close to a ‘cure.' "
The final patient has performed the last visit of the main study period in Diamyd Medical's European Phase III study. Treatment with the antigen based therapy Diamyd® is made to investigate whether beta cell function and thereby blood sugar control can be preserved in children and adolescents with new onset type 1 diabetes. The top line results from this study are expected to be reported as planned, in late spring 2011.
It's generally thought that a genetic predisposition to type 1 diabetes is not enough to develop the disease, but that an environmental trigger is required to activate it. Researchers are not sure what that environmental trigger is, but enteroviruses have been under suspicion for quite a while. Enteroviruses are the second leading cause of viral colds in children.
INDIANAPOLIS and NEW YORK - Eli Lilly and Company and the Juvenile Diabetes Research Foundation (JDRF) today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
The MOLLY and LINDSEY Diabetes Research Foundation at Hackensack University Medical Center (HUMC) and the Diabetes Research Institute (DRI), a Center of Excellence at the University of Miami Miller School of Medicine, have joined forces to find the cure for Type 1 Diabetes. Together they will form the Hackensack-Miami DRI Federation Project, a think tank of East Coast specialists who will fast-track the best research ideas coming out of the labs and put them to the test in clinically meaningful ways, thus shortening the path to a cure for those with type 1 diabetes.
(Reuters) - Stem cells can be transformed into the pancreatic cells needed to treat diabetes and into complex layers of intestinal tissue, scientists demonstrated in two experiments reported on Sunday.
"Congress passed a multi-year renewal of the Special Diabetes Program (SDP), ensuring that studies on promising diabetes treatments and avenues toward a cure continue uninterrupted. As the father of a son living with type 1 diabetes, and as CEO of JDRF, one of the leading advocates for the renewal of this program, I applaud the U.S. government for its continued commitment to end this disease.
Celebrate the season with an eCard and help support the Diabetes Research Institute! Send your family, friends or business colleagues A Gift of Love...A Gift of Hope. They will feel special knowing you are supporting research to find a cure for diabetes.
The presence of amyloid protein may produce a chain reaction which destroys vital insulin-producing cells. Researchers based in Dublin, writing in the journal Nature Immunology, say future drugs could target this process. Amyloid is implicated in many other diseases - most notably Alzheimer's.
In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease-offering clues to potential treatments for preserving and even restoring the crucial cell population.
MannKind Corporation announced that the company will supply its novel, ultra rapid acting insulin AFREZZATM (insulin human [rDNA origin]) for use in a study being conducted by the Juvenile Diabetes Research Foundation (JDRF) as part of its Artificial Pancreas Project. The planned two-year study in patients with type 1 diabetes will leverage the unique rapid action of AFREZZA for use in a closed-loop blood sugar monitoring and insulin delivery system, termed the "artificial pancreas" by the JDRF. The study will be managed in conjunction with the Sansum Diabetes Research Institute and the University of California, Santa Barbara.
"The objective of this clinical trial (research study) is to determine if the medications can rescue the few beta cells that remain soon after the diagnosis of type 1 diabetes; and whether new beta cells can even be regenerated," commented Alex Rabinovitch, MD, Principal Investigator of the trial and Associate Director of The Sanford Project. "The investigational combinations of these medications could possibly allow patients to decrease or no longer need to inject insulin to keep their blood levels under proper control."
City of Hope researchers have found that bone marrow transplantation with islet cell transplantation shows promise as a treatment for late-stage type 1 diabetes. This combination may enable patients to make their own insulin again. Results from laboratory research led by Defu Zeng, MD, associate professor in the departments of Diabetes Research and Hematology & Hematopoietic Cell Transplantation at City of Hope, were published online this month in the journal Diabetes.
Researchers from the National Jewish Health and University of Colorado Anschutz Medical Campus have found a specific protein fragment, or peptide, that stimulates an immune system attack resulting in diabetes. Their experiments in mice contradict conventional wisdom about such peptides and support work by scientists studying autoimmune diseases.
IMIDIA ("Innovative Medicines Initiative for Diabetes"), a public private consortium funded by the Innovative Medicines Initiative (IMI), announced today the launch of a project focusing on pancreatic islet cell function and survival. Academia, biotech and pharma industry have joined forces to develop biomarkers and tools to pave the way for improved disease management and ultimately provide a cure for diabetes.
Osiris Therapeutics announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
NEW YORK, April 27, 2010 - The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies (LCT), a New Zealand-based biotechnology company focused on developing cell based therapeutics, in a Phase II clinical trial to study the safety and effectiveness of transplanting encapsulated insulin-producing cells from pigs as a treatment for type 1 diabetes with significant hypoglycemia unawareness.
Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully reverse type 1 diabetes in mice and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.
A hormone responsible for the body's stress response is also linked to the growth of insulin-producing cells in the pancreas, according to JDRF- funded researchers at the Salk Institute for Biological Studies in California. The findings are the latest advances to underscore the potential for regeneration as a key component of a possible cure for type 1 diabetes.
How careful should healthcare workers and patients be in describing a total remission of diabetes as a "cure?" That's a question that has taken on increasing urgency in the wake of reports about dramatic reversals of type 2 symptoms after gastric bypass surgery and the cessation of symptoms in people with type 1 diabetes after pancreatic islet replacement. To answer it, a group of endocrinologists met earlier this year to come up with descriptions and definitions that accurately describe what happens when people with diabetes experience a reversal of symptoms.
These amazing teens-selected from 20,000 entries nationwide-were named State Honorees (along with 102 other state winners throughout the U.S.) in the 14th annual Prudential Spirit of Community Awards, a national program honoring middle and high school students for their outstanding acts of volunteerism. The program is conducted by Prudential Financial and the National Association of Secondary School Principals. Over the past 14 years, they have honored more than 80,000 young volunteers at the local, state, and national levels.
"Medical miracles do not happen simply by accident," said President Obama, as he signed an executive order lifting the ban on federally funded embryonic stem cell research. The Juvenile Diabetes Research Foundation (JDRF) is celebrating President Obama's new policy. They recently released this statement by Mary Tyler Moore, the International Chairman of the JDRF:
Nearly every time that I mention islet transplantation in a conversation about diabetes, the person I'm with responds with a sniff that it's never going to work because of the immune suppression problem.
The first time I presented medical research findings, I was not yet a physician. The year was about 1975. I was in my early forties and a mid-career engineer. The forum was a scientific symposium on diabetes. At the time, I felt that I had discovered the holy grail of diabetes care and was eager to share what I had learned.
I am always impressed when people find the strength to turn their own painful experience into a way to help others. In case you are losing faith that people are out there raising money, trying to find the Cure, and taking care of each other...read on.
To keep pace with the growing number of Americans with diabetes, the American Diabetes Association (ADA) invites communities nationwide to their brand new fundraising walk, Step Out: Walk to Fight Diabetes.
In March, Diabetes Health reported on Dr. Francesco Rubino, a surgeon who claims that the origin of diabetes is in the digestive system, not the gut, and that gastric bypass surgery cures type 2 diabetes.
Twenty-four diabetes doctors and researchers from the United States, Canada, the United Kingdom, Finland, Sweden and Portugal have published a study criticizing the American Diabetes Association (ADA) assertion that diabetics should consume no fewer than 130 mg of carbohydrates daily and the European Association for the Study of Diabetes (EASD) statement that low-carb diets are “not justified.”
The blood pressure medicine Tekturna (aliskiren) may have a beneficial side effect for people with type 2 diabetes and high blood pressure who are at risk of kidney disease. According to a recent article in The New England Journal of Medicine, the drug reduces proteinuria, a key indicator of kidney disease, by 20 percent in patients with type 2 diabetes.
Clinical trials have been a staple of diabetes research ever since 1922, when doctors in a Toronto hospital injected a young boy dying from the disease with pancreatic extracts. (The extracts contained the recently discovered hormone, insulin. The boy survived and lived another 13 years.)
Since the 1950s, the National Institutes of Health (NIH) has funded
almost all diabetes research worldwide. From its headquarters in
Bethesda, Maryland, the NIH oversees a $28 billion annual medical
research budget. More than $1 billion of those taxpayer dollars go
specifically toward diabetes research. Still, a cure remains
MINNEAPOLIS, Minn. - For the millions of people worldwide who are afflicted with diabetes, we are now one step closer to a potential cure for the disease. Spring Point Project, a non-profit organization created to expedite the widespread availability of islet tissue for diabetes care, will open its first biosecure animal facility in Western Wisconsin in February to hold high-health pathogen-free pigs. Insulin-producing islet cells from pigs are needed to meet the demands that cannot be realized by using transplantation of human islets.
Two and a half years ago, the journal Science published results from Denise Faustman’s groundbreaking study in which type 1 diabetes was reversed in non-obese diabetic mice injected with a combination of an immune adjuvant and spleen cells. Recently, researchers at the University of Chicago, Washington University in St. Louis and Harvard’s Joslin Clinic all partially replicated Dr. Faustman’s research.
Researchers may have discovered a protein in the liver that could lead to a cure for type 2 diabetes, according to a new study published in the February 19, 2002, issue of Nature Genetics. Doctors at the Medical College of Ohio found that this protein, called CEACAM1, helps to clear insulin from the blood.
Fetal tissue. No other topic in diabetes research is as emotionally stirring. Some say that fetal tissue is the key to progress, and perhaps that fetal tissue will even cure diabetes. Others claim that fetal tissue research is immoral because it produces an incentive for abortions. How important is fetal tissue research? Is it likely to produce a cure for diabetes? Are there alternatives that avoid ethical concerns?
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health.
Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.